Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23

DOI: 10.1158/2159-8290.CD-19-0154 Published November 2019

Online Impact

Volume 9, Issue 11, pp. 1511-1519

DOI

PubMed

Published By

Print ISSN

Online ISSN

History

¹The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
²St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia.
³Cancer Research Center of Lyon, INSERM UMR 1052, CNRS UMR 5286, Centre Leon Berard, Lyon, France.
⁴Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
⁵IGF, Universite de Montpellier, CNRS, INSERM, Montpellier, France.
⁶Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
⁷Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
⁸Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
⁹Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

↵*Corresponding Authors:
Maya Kansara, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW, Sydney, Australia. Phone: 61-0-2-9355-5779; E-mail: m.kansara{at}garvan.org.au; and David M. Thomas, Phone: 61-0-2-9355-5770; E-mail: d.thomas{at}garvan.org.au